Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 5/20 | 1.00 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 1.00 |
| ▸ | EGLN1 | Q9GZT9 | 17/20 | 0.58 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.56 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.56 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 0.51 |
| ▸ | VEGFA | P15692 | 2/20 | 0.51 |
| ▸ | FLT1 | P17948 | 2/20 | 0.51 |
| ▸ | KDM6B | O15054 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.51 |
| ▸ | TET3 | O43151 | 1/20 | 0.51 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.51 |
| ▸ | ASPH | Q12797 | 1/20 | 0.51 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.51 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.51 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.51 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.51 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25934714 | 0.85 | FTO (0.74) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL14122981 | 0.85 | FTO (0.74) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL1921281 | 0.84 | EGLN2 (0.72) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL8779266 | 0.83 | EGLN2 (0.70) | FTOEGLN2EGLN1TLR7EGLN3 | |
| SCHEMBL24405060 | 0.82 | FTO (0.69) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL22804019 | 0.82 | FTO (0.69) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL29601607 | 0.82 | FTO (0.69) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL8883374 | 0.82 | FTO (0.69) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL27039728 | 0.82 | FTO (0.69) | FTOEGLN2EGLN1KDM5BKDM2A | |
| SCHEMBL23514351 | 0.81 | FTO (0.69) | FTOEGLN2TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115018281-B | Network approximately special bus and subway intermodal matching optimization method | 北京交通大学 | 2025-03-28 | — | — | CN | claimed |
| CN-118590406-A | Ethernet-based data center lossless network grade test method | 中国信息通信研究院 | 2024-09-03 | — | — | CN | claimed |
| CN-117557019-A | Heat supply system scheduling method of heat pump-containing cluster based on model predictive control | 浙江英集动力科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| US-20230248717-A1 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2023-08-10 | — | — | US | claimed |
| CN-115511928-A | Matching method of multispectral image | 武汉大学 | 2022-12-23 | — | — | CN | claimed |
| CN-112979541-B | N- (3-hydroxypyridine-2-carbonyl) glycine-based antitumor drug sensitizer and application thereof | 浙江大学 | 2022-11-11 | — | — | CN | claimed |
| CN-115018281-A | Method for optimizing intermodal transportation matching of network contract private bus and subway | 北京交通大学 | 2022-09-06 | — | — | CN | claimed |
| EP-3520784-A1 | HIF PROLYL HYDROXYLASE INHIBITOR FOR TREATMENT OF ANEMIA | Fibrogen, Inc. (US) | 2019-08-07 | — | — | EP | claimed |
| CN-101664553-B | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN INC | 2013-08-21 | — | — | CN | claimed |
| CN-101664551-B | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN INC | 2013-08-14 | — | — | CN | claimed |
| US-20100168152-A1 | Fat regulation | FIBROGEN, INC. (US) | 2010-07-01 | — | — | US | claimed |
| CN-101664409-A | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN INC | 2010-03-10 | — | — | CN | claimed |
| US-7618940-B2 | Fat regulation | FIBROGEN, INC. (US) | 2009-11-17 | — | — | US | claimed |
| EP-2044005-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| US-5620995-A | Substituted heterocyclic carboxyamides, their preparation and their use as pharmaceuticals | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | claimed |
| EP-0661269-B1 | Substituted heterocyclic carboxylic acid amides, their preparation and their use as medicaments | HOECHST AG (DE) | 1997-03-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | FTO 4661/4885EGLN2 370/4885EGLN1 863/4885 |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | FTO 1298/4885EGLN2 5/4885EGLN1 6/4885 |
| US-20230248717-A1 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | IDO1, PDCD1, IDO2 | FTO 1432/4885EGLN2 21/4885EGLN1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.